205 related articles for article (PubMed ID: 34690920)
21. Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer.
Sokol ES; Feng YX; Jin DX; Basudan A; Lee AV; Atkinson JM; Chen J; Stephens PJ; Frampton GM; Gupta PB; Ross JS; Chung JH; Oesterreich S; Ali SM; Hartmaier RJ
Ann Oncol; 2019 Jan; 30(1):115-123. PubMed ID: 30423024
[TBL] [Abstract][Full Text] [Related]
22. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
[TBL] [Abstract][Full Text] [Related]
23. Single-Agent Abemaciclib Active in Breast Cancer.
Cancer Discov; 2016 Aug; 6(8):809-10. PubMed ID: 27354271
[TBL] [Abstract][Full Text] [Related]
24. Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients.
Liu J; Li J; Wang H; Wang Y; He Q; Xia X; Hu ZY; Ouyang Q
J Transl Med; 2019 Jan; 17(1):27. PubMed ID: 30646914
[TBL] [Abstract][Full Text] [Related]
25. A Single-centre, Retrospective, Observational Analysis of Fulvestrant for Recurrent/metastatic Breast Cancer According to Metastatic Site.
Ozawa H; Sata A; Fukui R; Bun A; Higuchi T; Fujimoto Y; Miyagawa Y; Imamura M; Miyoshi Y
Anticancer Res; 2019 Oct; 39(10):5653-5662. PubMed ID: 31570463
[TBL] [Abstract][Full Text] [Related]
26. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
27. Invasive lobular breast cancer presenting an unusual metastatic pattern in the form of peritoneal and rectal metastases: a case report.
Saranovic D; Kovac JD; Knezevic S; Susnjar S; Stefanovic AD; Saranovic DS; Artiko V; Obradovic V; Masulovic D; Micev M; Pesko P
J Breast Cancer; 2011 Sep; 14(3):247-50. PubMed ID: 22031809
[TBL] [Abstract][Full Text] [Related]
28. Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.
Palumbo A; Lau G; Saraceni M
Ann Pharmacother; 2019 Feb; 53(2):178-185. PubMed ID: 30099886
[TBL] [Abstract][Full Text] [Related]
29. [A Case Report of Metastatic Breast Cancer with Peritoneal Metastasis and Massive Ascites Responding to CDK4/6 Inhibitor(Palbociclib)].
Yao S; Goi T; Takahashi M; Kono H; Yokoi S; Maeda H
Gan To Kagaku Ryoho; 2024 Feb; 51(2):214-216. PubMed ID: 38449417
[TBL] [Abstract][Full Text] [Related]
30. Abemaciclib for the treatment of breast cancer.
Kotake T; Toi M
Expert Opin Pharmacother; 2018 Apr; 19(5):517-524. PubMed ID: 29522364
[TBL] [Abstract][Full Text] [Related]
31. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
32. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
Lainé M; Fanning SW; Chang YF; Green B; Greene ME; Komm B; Kurleto JD; Phung L; Greene GL
Breast Cancer Res; 2021 May; 23(1):54. PubMed ID: 33980285
[TBL] [Abstract][Full Text] [Related]
33. Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer.
Richard F; Majjaj S; Venet D; Rothé F; Pingitore J; Boeckx B; Marchio C; Clatot F; Bertucci F; Mariani O; Galant C; Eynden GVD; Salgado R; Biganzoli E; Lambrechts D; Vincent-Salomon A; Pruneri G; Larsimont D; Sotiriou C; Desmedt C
Clin Cancer Res; 2020 Dec; 26(23):6254-6265. PubMed ID: 32943456
[TBL] [Abstract][Full Text] [Related]
34. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
[TBL] [Abstract][Full Text] [Related]
35. Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.
Campone M; Im SA; Iwata H; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Cortés J; De Laurentiis M; Arteaga CL; Jiang Z; Jonat W; Le Mouhaër S; Sankaran B; Bourdeau L; El-Hashimy M; Sellami D; Baselga J
Eur J Cancer; 2018 Nov; 103():147-154. PubMed ID: 30241001
[TBL] [Abstract][Full Text] [Related]
36. [Development of CDK4 & 6 Inhibitor Abemaciclib in Breast Cancer].
Masuda N; Saji S; Kawaguchi T; Chen Y; Ohno S
Gan To Kagaku Ryoho; 2021 Dec; 48(12):1475-1483. PubMed ID: 34911915
[TBL] [Abstract][Full Text] [Related]
37. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
38. Fatal acute hepatic failure secondary to thrombotic portal venopathy after commencing abemaciclib and fulvestrant treatment for advanced breast carcinoma: a unique autopsy finding.
Haynes HR; Mohan V; Mozayani B; Gallagher P
Breast J; 2021 Jul; 27(7):612-614. PubMed ID: 33987967
[TBL] [Abstract][Full Text] [Related]
39. An evaluation of fulvestrant for the treatment of metastatic breast cancer.
Soleja M; Raj GV; Unni N
Expert Opin Pharmacother; 2019 Oct; 20(15):1819-1829. PubMed ID: 31486688
[No Abstract] [Full Text] [Related]
40. CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer: A network meta-analysis.
Huang HW; Huang LS; Xu QN; Wang HB; Li XY; Lin JZ
Medicine (Baltimore); 2019 Jan; 98(1):e13909. PubMed ID: 30608416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]